Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition-Reference-Cited by-同舟云学术

Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition

Published:2016-11-01 Issue:14 Volume:57 Page:5864
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Rush Jamie S.¹,Bingaman David P.²,Chaney Paul G.²,Wax Martin B.³,Ceresa Brian P.⁴

Affiliation:

1. Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, United States

2. PanOptica, Inc., Bernardsville, New Jersey, United States

3. PanOptica, Inc., Bernardsville, New Jersey, United States 3Department of Ophthalmology and Visual Sciences, Rutgers New Jersey Medical School Newark, New Jersey, United States

4. Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, United States 4Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, Kentucky, United States

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration;Journal of Translational Medicine;2023-02-21

2. Potential application of menadione for antimicrobial coating of surgical sutures;Biotechnology Notes;2023

3. Effect of vitamin K on wound healing: A systematic review and meta-analysis based on preclinical studies;Frontiers in Pharmacology;2022-12-02

4. Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye?;Frontiers in Drug Delivery;2022-09-08

5. A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration;American Journal of Ophthalmology;2022-07